Evacetrapib

Stephen Nicholls

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Considerable attention focuses on the ability to develop therapeutic agents that elevate levels of high-density lipoprotein cholesterol (HDL-C). Cholesteryl ester transfer protein (CETP) inhibitors have been developed on the basis of their ability to raise HDL-C to a greater extent than lipidmodifying therapies currently used in clinical practice. Initial enthusiasm for CETP inhibition decreased as a result of adverse clinical outcomes observed with the agent torcetrapib. Elucidating off-target toxicities of torcetrapib has provided hope that other CETP inhibitors may still be of potential benefit. Evacetrapib is a novel CETP inhibitor, with favorable effects on plasma lipids and no adverse effects on blood pressure or mineralocorticoid activity in early clinical evaluation. The potential effects on cardiovascular outcomes remain to be determined.

LanguageEnglish
Pages245-250
Number of pages6
JournalCurrent Cardiology Reports
Volume14
Issue number3
DOIs
Publication statusPublished - 1 Jun 2012

Keywords

  • Atherosclerosis
  • Cholesteryl ester transfer protein
  • Evacetrapib
  • High-density lipoprotein
  • Low-density lipoprotein
  • Risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Nicholls, Stephen. / Evacetrapib. In: Current Cardiology Reports. 2012 ; Vol. 14, No. 3. pp. 245-250.
@article{cf69b4247d1444cf964d390808b5588c,
title = "Evacetrapib",
abstract = "Considerable attention focuses on the ability to develop therapeutic agents that elevate levels of high-density lipoprotein cholesterol (HDL-C). Cholesteryl ester transfer protein (CETP) inhibitors have been developed on the basis of their ability to raise HDL-C to a greater extent than lipidmodifying therapies currently used in clinical practice. Initial enthusiasm for CETP inhibition decreased as a result of adverse clinical outcomes observed with the agent torcetrapib. Elucidating off-target toxicities of torcetrapib has provided hope that other CETP inhibitors may still be of potential benefit. Evacetrapib is a novel CETP inhibitor, with favorable effects on plasma lipids and no adverse effects on blood pressure or mineralocorticoid activity in early clinical evaluation. The potential effects on cardiovascular outcomes remain to be determined.",
keywords = "Atherosclerosis, Cholesteryl ester transfer protein, Evacetrapib, High-density lipoprotein, Low-density lipoprotein, Risk factors",
author = "Stephen Nicholls",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s11886-012-0252-3",
language = "English",
volume = "14",
pages = "245--250",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "3",

}

Nicholls, S 2012, 'Evacetrapib', Current Cardiology Reports, vol. 14, no. 3, pp. 245-250. https://doi.org/10.1007/s11886-012-0252-3

Evacetrapib. / Nicholls, Stephen.

In: Current Cardiology Reports, Vol. 14, No. 3, 01.06.2012, p. 245-250.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evacetrapib

AU - Nicholls, Stephen

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Considerable attention focuses on the ability to develop therapeutic agents that elevate levels of high-density lipoprotein cholesterol (HDL-C). Cholesteryl ester transfer protein (CETP) inhibitors have been developed on the basis of their ability to raise HDL-C to a greater extent than lipidmodifying therapies currently used in clinical practice. Initial enthusiasm for CETP inhibition decreased as a result of adverse clinical outcomes observed with the agent torcetrapib. Elucidating off-target toxicities of torcetrapib has provided hope that other CETP inhibitors may still be of potential benefit. Evacetrapib is a novel CETP inhibitor, with favorable effects on plasma lipids and no adverse effects on blood pressure or mineralocorticoid activity in early clinical evaluation. The potential effects on cardiovascular outcomes remain to be determined.

AB - Considerable attention focuses on the ability to develop therapeutic agents that elevate levels of high-density lipoprotein cholesterol (HDL-C). Cholesteryl ester transfer protein (CETP) inhibitors have been developed on the basis of their ability to raise HDL-C to a greater extent than lipidmodifying therapies currently used in clinical practice. Initial enthusiasm for CETP inhibition decreased as a result of adverse clinical outcomes observed with the agent torcetrapib. Elucidating off-target toxicities of torcetrapib has provided hope that other CETP inhibitors may still be of potential benefit. Evacetrapib is a novel CETP inhibitor, with favorable effects on plasma lipids and no adverse effects on blood pressure or mineralocorticoid activity in early clinical evaluation. The potential effects on cardiovascular outcomes remain to be determined.

KW - Atherosclerosis

KW - Cholesteryl ester transfer protein

KW - Evacetrapib

KW - High-density lipoprotein

KW - Low-density lipoprotein

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84861100469&partnerID=8YFLogxK

U2 - 10.1007/s11886-012-0252-3

DO - 10.1007/s11886-012-0252-3

M3 - Article

VL - 14

SP - 245

EP - 250

JO - Current Cardiology Reports

T2 - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 3

ER -